Provided by Tiger Fintech (Singapore) Pte. Ltd.

Therapeutics

25.45
+1.054.30%
Volume:131.28K
Turnover:3.30M
Market Cap:699.90M
PE:-9.47
High:25.69
Open:24.41
Low:24.30
Close:24.40
Loading ...

Bicycle Therapeutics Price Target Maintained With a $30.00/Share by Needham

Dow Jones
·
11 Mar

PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

Business Wire
·
11 Mar

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

GlobeNewswire
·
11 Mar

RBC Raises Price Target on Design Therapeutics to $5 From $4, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
11 Mar

Tenaya Therapeutics price target lowered to $5 from $18 at H.C. Wainwright

TIPRANKS
·
11 Mar

Checkpoint Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

TIPRANKS
·
11 Mar

Protara Therapeutics initiated with an Outperform at LifeSci Capital

TIPRANKS
·
11 Mar

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

StockStory
·
11 Mar

Optimistic Buy Rating for Aquestive Therapeutics Driven by Anaphylm NDA Submission and Strong Financial Position

TIPRANKS
·
11 Mar

Prelude Therapeutics Reports 2024 Financial Results

TIPRANKS
·
11 Mar

Aligos Therapeutics Advances Pipeline Amid Financial Challenges

TIPRANKS
·
11 Mar

Lineage Cell Therapeutics: 2024 Financial Results and Strategic Progress

TIPRANKS
·
11 Mar

Cathie Wood’s ARK Investment buys 485K shares of Beam Therapeutics today

TIPRANKS
·
11 Mar

Prescient Therapeutics Appoints Chair; Shares Fall 7%

MT Newswires Live
·
11 Mar

OnKure Therapeutics price target lowered to $30 from $35 at Oppenheimer

TIPRANKS
·
11 Mar

OnKure Therapeutics reports Q4 EPS ($1.37), consensus (86c)

TIPRANKS
·
11 Mar